Intellia Therapeutics Inc (NASDAQ: NTLA) is -37.82% lower on its value in year-to-date trading and has touched a low of $5.90 and a high of $28.18 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NTLA stock was last observed hovering at around $8.44 in the last trading session, with the day’s loss setting it -1.19%.
Currently trading at $7.25, the stock is -7.06% and -14.32% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.18 million and changing -14.10% at the moment leaves the stock -50.92% off its SMA200. NTLA registered -68.84% loss for a year compared to 6-month loss of -49.02%.
The stock witnessed a 9.35% gain in the last 1 month and extending the period to 3 months gives it a -24.64%, and is -11.59% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.63% over the week and 9.49% over the month.
Intellia Therapeutics Inc (NTLA) has around 403 employees, a market worth around $750.50M and $57.88M in sales. Profit margin for the company is -896.77%. Distance from 52-week low is 22.88% and -74.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.88%).
with sales reaching $11.99M over the same period.The EPS is expected to grow by 10.69% this year, but quarterly earnings will post -14.88% year-over-year. Quarterly sales are estimated to shrink -58.58% in year-over-year returns.
Intellia Therapeutics Inc (NTLA) Top Institutional Holders
The shares outstanding are 102.03M, and float is at 97.43M with Short Float at 29.26%.
The top institutional shareholder in the company is ARK INVESTMENT MANAGEMENT LLC with over 11.6 million shares valued at $259.51 million. The investor’s holdings represent 11.9575% of the NTLA Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.6 million shares valued at $214.79 million to account for 9.897 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 9.1 million shares representing 9.3839% and valued at over $203.66 million, while DEEP TRACK CAPITAL, LP holds 4.9497 of the shares totaling 4.8 million with a market value of $107.42 million.
Intellia Therapeutics Inc (NTLA) Insider Activity
The most recent transaction is an insider sale by Bhanji Muna, the company’s Director. SEC filings show that Bhanji Muna sold 265 shares of the company’s common stock on Apr 29 ’25 at a price of $8.50 per share for a total of $2252.0. Following the sale, the insider now owns 19203.0 shares.
Intellia Therapeutics Inc disclosed in a document filed with the SEC on Mar 04 ’25 that Clark Eliana (EVP, Chief Technical Officer) sold a total of 679 shares of the company’s common stock. The trade occurred on Mar 04 ’25 and was made at $8.99 per share for $6104.0. Following the transaction, the insider now directly holds 95369.0 shares of the NTLA stock.
Still, SEC filings show that on Mar 04 ’25, BASTA JAMES (EVP, General Counsel) disposed off 2,572 shares at an average price of $8.99 for $23122.0. The insider now directly holds 111,925 shares of Intellia Therapeutics Inc (NTLA).
